TY - JOUR
T1 - The status of antithymocyte globulin therapy for adult patients in Japan
T2 - Retrospective analysis of a nationwide survey
AU - Hattori, Mamiko
AU - Terasawa, Teruhiko
AU - Tsushita, Keitaro
AU - Utsumi, Makoto
AU - Kawano, Fumio
AU - Saito, Hidehiko
AU - Shimoyama, Masanori
AU - Ohashi, Haruhiko
N1 - Funding Information:
Medical and Pharmaceutical University Hospital, University of Fukui Hospital, Fukui Prefectural Hospital, Fukui Red Cross Hospital, NTT West Kanazawa Hospital, Ishikawa Prefectural General Hospital, Omihachiman City Hospital, Otsu Municipal Hospital, Otsu Red-Cross Hospital, Shiga University of Medical Science Hospital, Shiga Medical Center for Adults, Social Insurance Shiga Hospital, Takeda Hospital, Kyoto-katsura Hospital, Kyoto Second Red Cross Hospital, Kyoto Prefectural University of Medicine Hospital, National Hospital Organization Kyoto Medical Center, Maizuru Municipal Hospital, PL Hospital, Izumi City Hospital, Osaka Medical College Hospital, Osaka City General Hospital, Osaka City University Medical Hospital, Osaka Red Cross Hospital, Osaka University Hospital, Noe Saiseikai Hospital, Osaka Medical Center for Cancer and Cardiovascular Diseases, Yao City Hospital, Kansai Medical University Hospital, Kansai Denryoku Hospital, Kitano Hospital, Koudokai Hospital, Kishiwada City Hospital, Sakai Municipal Hospital, Suita Municipal Hospital, Toyonaka Municipal Hospital, Matsubara Municipal Hospital, Hokusetsu General Hospital, Akashi Municipal Hospital, Kinki Central Hospital, Kobe University Hospital, Kakog-awa Hospital, National Hospital Organization Himeji Medical Center, Nishi-Kobe Medical Center, St. Mary’s Hospital, The Hospital of Hyogo College of Medicine, Hyogo Prefectural Amagasaki Hospital, Hyogo Medical Center for Adults, Nara Prefectural Nara Hospital, Tenri Hospital, Wakayama Medical University Hospital, Kitaoka Hospital, Masuda Red Cross Hospital, Okayama Saiseikai General Hospital, Okayama Rosai Hospital, Hiroshima City Hospital, Chug-oku Central Hospital, Iwakuni Medical Center, Yamaguchi University Hospital, Naruto Hospital, Ehime Prefectural Central Hospital, Uwajima City Hospital, Matsuyama Red Cross Hospital, Kochi Medical School Hospital, Kochi Municipal Central Hospital, Kochi Red Cross Hospital, Kyushu University Faculty of Medicine, Kurume University Hospital, Kokura Memorial Hospital, Hamanomachi Hospital, Sin-Koga-Hospital, Saga Medical School Hospital, Nagasaki University Hospital, The Japanese Red Cross Nagasaki Atomic Bomb Hospital, NTT West Kyushu General Hospital, Japanese Kumamoto Red Cross Hospital, National Hospital Organization Kumamoto Medical Center, Oita Memorial Hospital, Oita Prefectural Hospital, Oita City Medical Association Almeida Hospital, Nankai Hospital, Koga General Hospital, Miyazaki Medical College Hospital, Miyazaki Prefectural Miyazaki Hospital, Imamura Bunin Hospital, Kagoshima City Hospital, Okinawa Chubu Hospital, Okinawa Prefecture Naha Hospital. We also thank Ms. Iwasaki for her excellent clerical assistance. This work was supported in part by a grant for the Department of Clinical Research, Nagoya National Hospital, the Ministry of Health and Welfare, Japan, and by a grant from the Research Committee for Idiopathic Hematopoietic Disorders, the Ministry of Health, Labour, and Welfare, Japan.
Funding Information:
Definition of the severity of aplastic anemia, proposed by The Research Committee for Idiopathic Hematopoietic Disorders supported by the Ministry of Health, Labour and Welfare of Japan.
PY - 2008/1
Y1 - 2008/1
N2 - We conducted a nationwide survey on antithymocyte globulin (ATG) therapy for adult patients in Japan. We mailed questionnaires to 454 hospitals with hematology divisions, of which 181 (40%) responded, and the records of 448 patients were collected. Patient characteristics, hematological responses, and adverse effects were evaluated in 421 patients with sufficient data. A total of 366 patients had idiopathic aplastic anemia (AA), 29 had other types of AA, and 25 had other diseases. The response rate (RR) at 6 months was 54% for all patients, and 53% for those with idiopathic AA. Ten patients (2%) died within 30 days, and 11 (3%) died between 31 and 100 days after ATG therapy. In 346 patients with moderate to very severe AA, who received their first ATG therapy, factors that influence the outcomes of ATG therapy were extracted. Among 11 pre-treatment and therapy-related variables, three were found to be correlated with a higher RR: shorter duration of AA, no history of specific therapy for AA, and the use of CsA. Most notably, the RR of patients treated within 3 months of diagnosis, those between 3 months and 2 years, and those later than 2 years were 68% (130/190), 48% (54/113), and 13% (5/38), respectively.
AB - We conducted a nationwide survey on antithymocyte globulin (ATG) therapy for adult patients in Japan. We mailed questionnaires to 454 hospitals with hematology divisions, of which 181 (40%) responded, and the records of 448 patients were collected. Patient characteristics, hematological responses, and adverse effects were evaluated in 421 patients with sufficient data. A total of 366 patients had idiopathic aplastic anemia (AA), 29 had other types of AA, and 25 had other diseases. The response rate (RR) at 6 months was 54% for all patients, and 53% for those with idiopathic AA. Ten patients (2%) died within 30 days, and 11 (3%) died between 31 and 100 days after ATG therapy. In 346 patients with moderate to very severe AA, who received their first ATG therapy, factors that influence the outcomes of ATG therapy were extracted. Among 11 pre-treatment and therapy-related variables, three were found to be correlated with a higher RR: shorter duration of AA, no history of specific therapy for AA, and the use of CsA. Most notably, the RR of patients treated within 3 months of diagnosis, those between 3 months and 2 years, and those later than 2 years were 68% (130/190), 48% (54/113), and 13% (5/38), respectively.
UR - https://www.scopus.com/pages/publications/41849133209
UR - https://www.scopus.com/pages/publications/41849133209#tab=citedBy
U2 - 10.1007/s12185-007-0016-9
DO - 10.1007/s12185-007-0016-9
M3 - Article
C2 - 18224413
AN - SCOPUS:41849133209
SN - 0925-5710
VL - 87
SP - 48
EP - 55
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 1
ER -